Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021085650 - VACCINE

Publication Number WO/2021/085650
Publication Date 06.05.2021
International Application No. PCT/JP2020/041112
International Filing Date 02.11.2020
IPC
A61K 39/145 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
145Orthomyxoviridae, e.g. influenza virus
A61P 31/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
16for influenza or rhinoviruses
A61P 37/04 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
04Immunostimulants
A61K 47/64 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C12N 15/24 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
19Interferons; Lymphokines; Cytokines
24Interleukins
C12N 15/44 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
44Orthomyxoviridae, e.g. influenza virus
CPC
A61K 39/145
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
145Orthomyxoviridae, e.g. influenza virus
A61K 47/64
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61P 31/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
16for influenza or rhinoviruses
A61P 37/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
04Immunostimulants
C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
Applicants
  • 有限会社根路銘生物資源研究所 NEROME INSTITUTE OF BIOLOGICAL RESOURCES [JP]/[JP]
Inventors
  • 根路銘 国昭 NEROME Kuniaki
  • 杉田 繁夫 SUGITA Shigeo
Agents
  • 田中 伸一郎 TANAKA Shinichiro
  • 山崎 一夫 YAMASAKI Kazuo
Priority Data
2019-19884531.10.2019JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) VACCINE
(FR) VACCIN
(JA) ワクチン
Abstract
(EN)
The objective is to provide a novel, highly effective vaccine. The present invention relates to a vaccine comprising a virus-like particle containing an immunomodulator molecule, wherein: the immunomodulator molecule includes interleukin-12 protein, a neuraminidase (NA) domain region originating from NA protein, and an M2 protein domain region originating from an influenza virus; the NA domain region includes an extramembrane domain, a transmembrane domain, and an intracellular domain; the M2 protein domain region includes an extramembrane domain, a transmembrane domain, and an intracellular domain; the interleukin-12 protein is bound to the extramembrane domain in the NA domain region; and the intracellular domain in the M2 protein domain region is bound to the intracellular domain in the NA domain region via a linker.
(FR)
La présente invention a pour objectif de produire un nouveau vaccin hautement efficace. À cet effet, la présente invention concerne un vaccin comprenant une particule du type virus contenant une molécule immunomodulatrice. La molécule immunomodulatrice comprend une protéine d'interleukine-12, une région d'un domaine de la neuraminidase (NA) issue de la protéine NA, et une région d'un domaine de la protéine M2 issue d'un virus de la grippe ; la région du domaine de la NA comprend un domaine extra-membranaire, un domaine transmembranaire et un domaine intracellulaire ; la région du domaine de la protéine M2 comprend un domaine extra-membranaire, un domaine transmembranaire et un domaine intracellulaire ; la protéine d'interleukine-12 est liée au domaine extra-membranaire dans la région du domaine de la NA ; et le domaine intracellulaire dans la région du domaine de la protéine M2 est lié au domaine intracellulaire dans la région du domaine de la NA par l'intermédiaire d'un lieur.
(JA)
新規かつ効果の高いワクチンを提供することを課題とする。 本発明は、免疫モジュレーター分子を含有するウイルス様粒子を含むワクチンであって、免疫モジュレーター分子が、インターロイキン12タンパク質と、ノイラミニダーゼ(NA)タンパク質由来のNAドメイン領域と、インフルエンザウイルス由来のM2タンパク質ドメイン領域とを含み、NAドメイン領域は、細胞膜外ドメインと、細胞膜貫通ドメインと、細胞質内ドメインとを含み、M2タンパク質ドメイン領域は、細胞膜外ドメインと、細胞膜貫通ドメインと、細胞質内ドメインとを含み、インターロイキン12タンパク質が、NAドメイン領域における、細胞膜外ドメインに結合され、M2タンパク質ドメイン領域における細胞質内ドメインが、NAドメイン領域における細胞質内ドメインとリンカーを介して結合された、ワクチンに関する。
Latest bibliographic data on file with the International Bureau